Research compounds
Adipotide
FTPP, Prohibitin-TP01
Adipotide is an experimental peptidomimetic designed to destroy the blood supply of white adipose tissue. It produced striking weight loss in obese rhesus monkeys in a 2011 study and has never completed a human trial. It is sold as a research chemical.
Also known as: FTPP, Prohibitin-TP01, CKGGRAKDC-GG-D(KLAKLAK)2
- Status
- Adipotide is a research compound and not approved by the FDA for human use.
- Evidence
- Preclinical. Evidence comes from animal or lab studies; effects in people are not established.
- Half-life
- Not established in humans.
- How it's taken
- Subcutaneous injection in non-clinical use
- Mechanism
- Metabolic (non-incretin)
How Adipotide works
Adipotide is a chimeric molecule: a homing sequence that binds prohibitin on the endothelium of white adipose tissue vasculature, fused to a pro-apoptotic sequence that disrupts mitochondrial membranes once internalised. The intended effect is targeted apoptosis of the blood vessels feeding fat tissue, causing the fat to resorb — an anti-angiogenic approach to obesity rather than an appetite or metabolic one.
What research has looked at
- In the widely cited rhesus monkey study, treated animals lost a substantial proportion of body weight over four weeks with reductions in abdominal fat and improved insulin sensitivity.
- The targeting concept — using a vascular address to direct a cytotoxic payload to a specific tissue — is a legitimate and interesting piece of science.
- The prohibitin marker it targets was identified through phage display screening of adipose vasculature, an established method for finding tissue-specific vascular addresses.
Evidence level: Preclinical. Evidence comes from animal or lab studies; effects in people are not established. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Renal toxicity was dose-dependent and was observed in the primate study. The kidney concentrates the peptide, and nephrotoxicity is the principal reason development did not progress.
- No completed human clinical trial has established either efficacy or safety, and there is no approved use anywhere.
- The mechanism is destructive rather than regulatory — it kills vasculature. The long-term consequences of ablating adipose vasculature in humans, including effects on adipose tissue endocrine function, are unknown.
- Material sold as adipotide is research chemical supply with unverified identity, purity, sterility and dose accuracy.
- The weight loss in the primate study reflected fat resorption after vascular destruction, not a metabolic or appetite mechanism, and it is not established that this is reversible or sustainable.
Sources
- PubMed research on adipotide prohibitin nephrotoxicity primate · NIH · National Library of Medicine
- DrugBank record for adipotide · DrugBank
- Active clinical trials for adipotide · U.S. National Library of Medicine
Track Adipotide in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Adipotide FAQ
What is Adipotide?
Adipotide is an experimental peptidomimetic designed to destroy the blood supply of white adipose tissue. It produced striking weight loss in obese rhesus monkeys in a 2011 study and has never completed a human trial. It is sold as a research chemical.
How does Adipotide work?
Adipotide is a chimeric molecule: a homing sequence that binds prohibitin on the endothelium of white adipose tissue vasculature, fused to a pro-apoptotic sequence that disrupts mitochondrial membranes once internalised. The intended effect is targeted apoptosis of the blood vessels feeding fat tissue, causing the fat to resorb — an anti-angiogenic approach to obesity rather than an appetite or metabolic one.
Is Adipotide FDA approved?
No. Adipotide is a research compound and not approved by the FDA for human use. Evidence level: preclinical. Evidence comes from animal or lab studies; effects in people are not established.
How is Adipotide taken?
Subcutaneous injection in non-clinical use.
What side effects have been reported with Adipotide?
Reported in the sources: Renal toxicity was dose-dependent and was observed in the primate study. The kidney concentrates the peptide, and nephrotoxicity is the principal reason development did not progress; No completed human clinical trial has established either efficacy or safety, and there is no approved use anywhere; The mechanism is destructive rather than regulatory — it kills vasculature. The long-term consequences of ablating adipose vasculature in humans, including effects on adipose tissue endocrine function, are unknown; Material sold as adipotide is research chemical supply with unverified identity, purity, sterility and dose accuracy; The weight loss in the primate study reflected fat resorption after vascular destruction, not a metabolic or appetite mechanism, and it is not established that this is reversible or sustainable.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.